After three years of collaboration, a team of academician-scientists from the UAE, US and Sweden has designed and developed peptides believe to inhibit the progress of another group of proteins and protect the brain from the neurodegenerative Alzheimer’s Disease.
There is a new form of Alzheimer’s Disease (AD) identified as “Progressive Dysexecutive Syndrome (dAD), the onset of which is by age 40.
The cost of caring for America’s nearly 6 million Alzheimer’s disease patients is already $600 billion a year, factoring in the cost of uncompensated caregiving. Now, the Food and Drug Administration has approved a drug treatment that may or may not work
My personal journey with Alzheimer’s began in 2005 when my wife, Valerie, received her diagnosis with this terrible disease, one that robs the afflicted of their minds and forces family and friends to watch with dread as their loved one slowly disappears.
When the US Food and Drug Administration approved Biogen Inc.’s controversial Alzheimer’s drug Aduhelm earlier this month without firm evidence that the drug helps patients, it created concern that other unproven treatments might follow. That scenario is already here.
He did not forget his love; “It was so perfect. I couldn’t have dreamt of a better day. It was so magical,” his wife, Lisa says.
The UAE Ministry of Health and Prevention on Sunday announced the approval after it got the go ahead call from the Food and Drug Administration (FDA) to start registration and use of the Biogen’s Aduhelm drug for Alzheimer’s disease.